These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9662367)

  • 1. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.
    Kohn DB; Hershfield MS; Carbonaro D; Shigeoka A; Brooks J; Smogorzewska EM; Barsky LW; Chan R; Burotto F; Annett G; Nolta JA; Crooks G; Kapoor N; Elder M; Wara D; Bowen T; Madsen E; Snyder FF; Bastian J; Muul L; Blaese RM; Weinberg K; Parkman R
    Nat Med; 1998 Jul; 4(7):775-80. PubMed ID: 9662367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
    Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
    Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
    N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
    Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
    Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
    Ferrua F; Brigida I; Aiuti A
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.
    Carbonaro DA; Jin X; Cotoi D; Mi T; Yu XJ; Skelton DC; Dorey F; Kellems RE; Blackburn MR; Kohn DB
    Blood; 2008 Jun; 111(12):5745-54. PubMed ID: 18356486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
    Kohn DB; Weinberg KI; Nolta JA; Heiss LN; Lenarsky C; Crooks GM; Hanley ME; Annett G; Brooks JS; el-Khoureiy A
    Nat Med; 1995 Oct; 1(10):1017-23. PubMed ID: 7489356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.
    Mortellaro A; Hernandez RJ; Guerrini MM; Carlucci F; Tabucchi A; Ponzoni M; Sanvito F; Doglioni C; Di Serio C; Biasco L; Follenzi A; Naldini L; Bordignon C; Roncarolo MG; Aiuti A
    Blood; 2006 Nov; 108(9):2979-88. PubMed ID: 16835374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
    Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
    Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
    Ramsey WJ; Mullen CA; Blaese RM
    Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates.
    Schmidt M; Carbonaro DA; Speckmann C; Wissler M; Bohnsack J; Elder M; Aronow BJ; Nolta JA; Kohn DB; von Kalle C
    Nat Med; 2003 Apr; 9(4):463-8. PubMed ID: 12640448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy.
    Otsu M; Hershfield MS; Tuschong LM; Muul LM; Onodera M; Ariga T; Sakiyama Y; Candotti F
    Hum Gene Ther; 2002 Feb; 13(3):425-32. PubMed ID: 11860709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.